6.58k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and drug stocks||-0.81%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||163.36||-1.17||-0.71%||16:00 GMT-4||8.46M||6.90M||429.50B|
|LLY||Eli Lilly and Company||323.35||-6.66||-2.02%||16:03 GMT-4||4.21M||2.73M||307.24B|
|RHHBY||Roche Holding AG||40.62||-0.49||-1.19%||16:00 GMT-4||1.99M||1.46M||272.58B|
|PFE||Pfizer Inc.||43.76||-0.40||-0.91%||16:03 GMT-4||21.64M||17.66M||245.60B|
|ABBV||AbbVie Inc.||134.21||-8.51||-5.96%||16:03 GMT-4||14.91M||5.51M||237.30B|
|NVO||Novo Nordisk A/S||99.63||-0.76||-0.76%||16:00 GMT-4||1.09M||1.68M||225.39B|
|MRK||Merck & Co., Inc.||86.12||-0.52||-0.60%||16:04 GMT-4||8.36M||8.17M||218.17B|
|NVS||Novartis AG||76.01||-0.56||-0.73%||16:00 GMT-4||2.25M||2.28M||169.07B|
|AZN||AstraZeneca PLC||54.84||-0.07||-0.13%||16:00 GMT-4||7.05M||6.49M||166.73B|
|BMY||Bristol-Myers Squibb Company||71.09||-0.62||-0.86%||16:00 GMT-4||10.80M||9.68M||151.80B|
|AMGN||Amgen Inc.||225.4||-3.01||-1.32%||16:00 GMT-4||2.54M||2.61M||120.57B|
|GILD||Gilead Sciences, Inc.||61.69||-1.38||-2.19%||16:00 GMT-4||8.79M||6.82M||77.32B|
|REGN||Regeneron Pharmaceuticals, Inc.||688.87||-2.95||-0.43%||16:00 GMT-4||800.89k||684.92k||75.09B|
|VRTX||Vertex Pharmaceuticals Incorporated||289.54||-3.26||-1.11%||16:00 GMT-4||1.91M||1.38M||74.26B|
|ZTS||Zoetis Inc.||148.29||-2.66||-1.76%||16:04 GMT-4||2.31M||1.68M||69.42B|
|GSK||GlaxoSmithKline plc||29.43||+0.07||+0.24%||16:00 GMT-4||6.63M||6.87M||57.98B|
|MRNA||Moderna, Inc.||118.25||+0.18||+0.15%||16:00 GMT-4||3.83M||4.84M||46.26B|
|BAYRY||Bayer Aktiengesellschaft||11.56||-0.16||-1.37%||15:59 GMT-4||873.54k||771.50k||45.78B|
|TAK||Takeda Pharmaceutical Company Limited||12.97||-||-||16:00 GMT-4||2.86M||2.46M||40.32B|
|BIIB||Biogen Inc.||267||+2.72||+1.03%||16:00 GMT-4||3.75M||1.26M||38.75B|
|BNTX||BioNTech SE||134.88||+1.28||+0.96%||16:00 GMT-4||735.18k||892.85k||32.73B|
|HLN||Haleon plc||6.09||-0.02||-0.33%||16:00 GMT-4||4.49M||9.27M||28.02B|
|RPRX||Royalty Pharma plc||40.18||-0.15||-0.37%||16:00 GMT-4||1.40M||1.82M||27.16B|
|SGEN||Seattle Genetics, Inc.||136.83||+1.13||+0.83%||16:00 GMT-4||676.80k||1.07M||25.24B|
|ALNY||Alnylam Pharmaceuticals, Inc.||200.16||-9.23||-4.41%||16:00 GMT-4||1.68M||1.04M||24.02B|
|GMAB||Genmab A/S||32.13||+0.20||+0.63%||16:00 GMT-4||773.25k||606.36k||20.85B|
|ARGX||argenx SE||353.05||-4.50||-1.26%||16:00 GMT-4||149.27k||254.95k||19.56B|
|BMRN||BioMarin Pharmaceutical Inc.||84.77||-0.29||-0.34%||16:00 GMT-4||1.44M||973.65k||15.72B|
|INCY||Incyte Corporation||66.64||+0.03||+0.05%||16:00 GMT-4||1.29M||1.39M||14.82B|
Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter. The Cambridge, Massachusetts-based pharmaceutical company turned down China’s request to hand over the recipe for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place between 2020 and 2021, adding that the vaccine maker is still “eager” to sell the product to China. The company had “given up” on its previous efforts to access the Chinese market because of China’s demand that it hand over the technology as a prerequisite for selling in the country, the report said.
Moderna has refused to hand over to China the core intellectual property behind the development of its breakthrough Covid-19 vaccine, leading to a collapse in negotiations on its sale there, according to multiple people familiar with the matter. The Massachusetts-based pharmaceutical company turned down Beijing’s request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still “eager” to sell the product to China.
The world's best-selling drug begins losing patent protections next year. AbbVie's revenue could take years to recover.